.svg)
.svg)
For decades, researchers working with rodent models have relied on the traditional PMSG-hCG method to induce superovulation. While this approach has been the gold standard for over 55 years, it comes with significant limitations that impact both research efficiency and animal welfare. The CARD HyperOva product line represents a major breakthrough in rodent reproductive biology, offering a superior alternative that addresses the key weaknesses of traditional methods.
Hyperovulation is the process of inducing female rodents to produce more eggs than normal, which is essential for in vitro fertilization, embryo transfer, and genetic research. Traditional methods use pregnant mare serum gonadotropin (PMSG) followed by human chorionic gonadotropin (hCG), but this approach has several drawbacks that researchers have had to work around for years.
The Traditional PMSG-hCG Method: Limitations and Challenges
The conventional approach for inducing superovulation in rodents involves consecutive injections of pregnant mare serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG). This method has been used for mouse superovulation for more than 55 years in many laboratories. However, this traditional approach comes with several significant problems that limit its effectiveness.
Low Egg Production
The biggest limitation of traditional methods is simply the low number of eggs produced. With conventional PMSG-hCG treatment, researchers typically get around 20 eggs per C57BL/6 mouse, one of the most commonly used strains. This means you need many more female mice to get enough eggs for your experiments, which increases costs and animal use.
Variable Results Between Strains
Response to gonadotropin injection varies from strain to strain. What works well for one mouse strain might give poor results for another. This variability makes it difficult to standardize protocols across different genetic backgrounds and means researchers often have to spend time doing preliminary dose response studies for each new strain they work with.
Poor Egg Quality
Superovulation in female mice increases the number of unhealthy follicles that ovulate and results in an increase in poor quality oocytes. The traditional method not only produces fewer eggs but also reduces the quality of the eggs that are produced. This leads to lower fertilization rates and fewer healthy embryos.
Negative Effects on Pregnancy
Superovulatory treatment causes changes in the unsuitable maternal oviduct and uterine environment which impair implantation and subsequent pregnancy in female mice and rats. These effects can make it harder to get pregnant females when doing embryo transfer procedures.
Repeated Treatment Problems
Furthermore, repeated ovarian stimulation promotes the apoptosis of ovarian cells and negatively affects ovarian cell function. This means that if you need to use the same breeding females multiple times, their response gets worse with each treatment.
Oxidative Stress and Damage
Recent research has shown that repeated PMSG/hCG treatment eventually leads to oxidative stress and damage in all reproductive organs of female mice. This cellular damage can affect both the short-term success of the procedure and the long-term health of the animals.
CARD HyperOva: A Superior Alternative
CARD HyperOva represents a breakthrough in rodent superovulation technology. This ultra-superovulation reagent was developed by the Center for Animal Resources and Development (CARD) at Kumamoto University, which has been at the forefront of reproductive technology development for over 25 years.
The Science Behind CARD HyperOva
CARD HyperOva is a mixture of equine chorionic gonadotropin and goat anti-inhibin antiserum. This combination works by blocking inhibin, a hormone that normally limits egg production. By neutralizing inhibin with the anti-inhibin antibodies, more follicles can develop and ovulate, leading to dramatically higher egg yields.
Dramatic Increase in Egg Production
The most impressive advantage of CARD HyperOva is its ability to produce 3-4 times more eggs than traditional methods. While conventional PMSG-hCG treatment typically yields around 20 eggs per C57BL/6 mouse, CARD HyperOva produces approximately 80 eggs from the same mouse. This represents a 300-400% improvement in efficiency.
Works Across Multiple Strains
Unlike traditional methods that show high variability between strains, CARD HyperOva is also effective with many other strains. Testing has shown consistent improvements across major inbred and outbred mouse strains, making it a more reliable choice for diverse research programs.
Improved Storage and Handling
CARD HyperOva can be stored refrigerated at 4°C by freeze-drying, which improved storage stability compared to conventional products. This makes it easier to keep the reagent on hand and reduces waste from expired products.
Optimized Protocol
The CARD HyperOva protocol has been refined through extensive research. The optimal protocol involves injecting 0.1-0.2 mL CARD HyperOva into 26-30 day old female mice, followed 48 hours later with 7.5 IU hCG. This timing has been optimized based on experiments showing that this age range produces the highest egg yields.
Practical Benefits for Researchers
Reduced Animal Use
Using CARD HyperOva® can reduce the number of oocyte donor mice by a factor of 1/3-1/4. This is a huge advantage for research programs focused on the 3Rs of animal welfare: replacement, reduction, and refinement. Getting more eggs from fewer animals means less time spent on breeding, housing, and handling animals.
Cost Savings
While the initial cost per dose of CARD HyperOva may be higher than traditional reagents, the total cost per egg produced is significantly lower. When you factor in the reduced animal costs, labor time, and higher success rates, the economic benefits become clear.
Better Project Planning
The higher and more consistent yields from CARD HyperOva make it easier to plan experiments. Instead of having to estimate how many donor females you might need based on variable traditional methods, you can more accurately predict your egg yields and plan accordingly.
Improved Efficiency for Valuable Strains
Using CARD HyperOva® on your valuable genetically modified mice enables you to obtain a lot of ova from small number of females, thus enabling the large-scale preparation of embryos. This is particularly important when working with rare or expensive genetically modified strains where every animal is precious.
Enhanced IVF Success
When combined with CARD MEDIUM during the IVF procedure, CARD HyperOva provides even further gains in efficiency. The CARD system has been designed as an integrated approach where the superovulation reagent works optimally with the specialized fertilization medium.
Better Handling Procedures
The CARD protocol has been refined to account for the much higher egg yields. When using CARD HyperOva, the oviducts of superovulating female mice swell significantly, so the protocol includes specific handling instructions to avoid damaging the swollen oviducts during egg collection.
Optimized Fertilization Parameters
The IVF protocol for CARD HyperOva differs from traditional protocols in important ways. The number of cumulus-oocyte complexes placed in each fertilization dish is reduced to 2, and the sperm suspension volume for insemination is adjusted to about 6μL. These modifications account for the much higher egg yields and help maintain optimal fertilization conditions.
Applications and Use Cases
Genetically Modified Mouse Programs
CARD HyperOva is particularly valuable for programs creating and maintaining genetically modified mice. The ability to get more eggs from fewer animals makes it much easier to establish new transgenic lines and maintain existing ones.
Cryopreservation Programs
Mouse banks and repositories benefit enormously from CARD HyperOva because it allows them to create larger numbers of embryos for freezing from fewer donor animals. This is crucial for preserving genetic diversity and ensuring the long-term availability of important research strains.
High-Throughput Screening
Research programs that need large numbers of embryos for screening or testing benefit from the increased efficiency. Instead of setting up numerous breeding pairs and multiple superovulation cycles, researchers can get the embryos they need from a single, more efficient procedure.
Embryo Transfer Programs
The higher egg yields from CARD HyperOva make embryo transfer procedures more efficient. With more embryos available from each IVF cycle, researchers can transfer more embryos per recipient or have backup embryos available if initial transfers don't succeed.
Comparison with Traditional Methods
Efficiency Comparison
Traditional PMSG-hCG treatment typically produces 15-25 eggs per mouse depending on the strain, while CARD HyperOva consistently produces 60-80 eggs per mouse. This 3-4 fold improvement means that a single CARD HyperOva treatment can replace 3-4 traditional treatments.
Animal Welfare Impact
The dramatic reduction in animal use represents a significant improvement in animal welfare. Instead of needing 20 female mice to produce enough eggs for a large experiment, researchers might only need 5-6 mice when using CARD HyperOva.
Success Rate Comparison
Traditional methods often require multiple attempts to get sufficient high-quality embryos, especially with difficult strains. The higher yields and better consistency of CARD HyperOva reduce the need for repeated attempts, saving time and resources.
Storage and Stability
While traditional PMSG and hCG require careful storage and have limited shelf life, CARD HyperOva's freeze-dried formulation offers better stability and easier handling. This reduces waste and ensures more consistent results.
Technical Considerations
Protocol Adaptation
Switching from traditional methods to CARD HyperOva requires some protocol adjustments, but these are well-documented and straightforward. The main changes involve the timing of injections, the age of female mice used, and the handling procedures during egg collection.
Quality Control
The standardized production of CARD HyperOva provides more consistent batch-to-batch results compared to traditional methods where hormone preparations can vary significantly between lots.
Training Requirements
While the basic injection and handling procedures are similar, researchers need to be trained on the specific protocols for CARD HyperOva, particularly the modified egg collection procedures that account for the swollen oviducts.
Future Directions and Improvements
Ongoing Research
The CARD team continues to refine and improve their hyperovulation technology. Recent research has focused on optimizing timing protocols and developing new formulations for different applications.
Expanded Applications
While initially developed for mice, research is ongoing to adapt similar approaches for other rodent species. The principles behind CARD HyperOva could potentially be applied to rats and other laboratory animals.
Integration with New Technologies
As new reproductive technologies emerge, CARD HyperOva provides a strong foundation for integration with techniques like genome editing, single-cell analysis, and advanced embryo culture systems.
Conclusion
CARD HyperOva represents a significant advancement over traditional PMSG-hCG methods for rodent hyperovulation. The combination of dramatically higher egg yields, improved consistency across strains, better storage stability, and reduced animal use makes it a superior choice for most research applications.
The 3-4 fold improvement in egg production translates directly into reduced animal use, lower costs, and more efficient research programs. For researchers working with valuable genetically modified strains, rare lines, or high-throughput applications, CARD HyperOva offers advantages that can't be matched by traditional methods.
The extensive research and development behind CARD HyperOva, combined with over 25 years of experience from the CARD center, provides confidence in both the science and the practical application of this technology. As research programs increasingly focus on efficiency, animal welfare, and reproducibility, CARD HyperOva provides a proven solution that addresses all these concerns.
While traditional PMSG-hCG methods have served the research community well for over half a century, the time has come to adopt better approaches. CARD HyperOva doesn't just improve on traditional methods - it transforms what's possible in rodent reproductive biology, making research more efficient, more humane, and more successful.
For research programs still relying on traditional hyperovulation methods, the question isn't whether to switch to CARD HyperOva, but how quickly you can implement this superior technology to improve your research outcomes.
This article reflects current scientific understanding based on peer-reviewed research and product literature. Researchers should consult current protocols and product specifications when implementing new hyperovulation methods.
